Stem Cell Therapy’s to be subsidiary, Histostem has been awarded US Patent Number 7,582,477 B2, entitled: “Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood.”
Reportedly, the patented method is utilised for research, clinical and cosmetic applications across the company. The patent is a central method for obtaining the primary ingredients in the development and manufacturing of the company’s stem cell facial cream, as well as for previous and anticipated future clinical trials.
The cream’s active ingredients include Human Stem Cell Conditioned Media (HSCM), which are proteins created during the culture of stem cells using Histostem’s patented method. The Stem Cell Cream helps to recover the function of the skin’s own stem cells, thereby vitalising the natural fibroblasts of the skin.
The patent, issued on September 1, 2009, included the description in its abstract: The present invention relates to a method of isolating and culturing mesenchymal stem cells using cryopreserved umbilical cord blood that is the most ideal for cell therapy. Additional development of Histostem technology by AmStem will include ensuring that their vast stockpile of cord blood units (CBUs) (and therapeutic stem cells derived from them using the newly-patented technique) will be available to researchers and patients in need around the world.
David Stark, president and CEO of Stem Cell Therapy, said: “Amstem, which will be the new merged company, has a unique three pronged platform in the market, a lab dedicated to clinical development of stem cell therapies for unmet medical needs, as well as compelling consumer products preparing for international distribution. Of particular relevance is its use in the development and manufacturing of our Stem Cell Facial Cream, which is used to rejuvenate the skin.
“We are actively exploring partnering opportunities with US and EU distribution partners. Given our proven market presence in Asia, proprietary supply chain, GMP-approved manufacturing facility, and study results, the response has been extremely positive.We will be making inroads to pool our accredited cord blood bank with other international repositories to facilitate the use of the CBU’s by patients in the fastest, most accurate way possible.”